Clinical TrialJun 30, 2026, 08:05 AM
Catalyst Pharma Vamorolone Phase 1 Study Shows Balanced Activity
AI Summary
Catalyst Pharmaceuticals announced positive topline results from a two-part Phase 1 clinical study of vamorolone in healthy adult volunteers. The study demonstrated balanced corticosteroid activity with expected cortisol suppression and no evidence of significant immunosuppressive activity at clinical doses. These findings suggest vamorolone delivers glucocorticoid and anti-inflammatory activity without significant immunosuppressant effects, supporting its potential use across various chronic inflammatory rare diseases.
Key Highlights
- Two-part Phase 1 study of vamorolone conducted in healthy adult volunteers.
- Part A assessed equipotency between vamorolone (300 mg) and deflazacort (0.9 mg/kg).
- Both agents showed expected on-target glucocorticoid receptor activity and comparable cortisol suppression.
- Vamorolone demonstrated less pronounced immunosuppressive biomarker effects compared to deflazacort.
- Part B evaluated ascending doses (9, 27, 40 mg/kg/day) of vamorolone for seven days.
- No relevant immunosuppressive effects observed at lower doses (9 or 27 mg/kg/day).
- Clinically relevant immunosuppressive effects were only observed at the highest dose (40 mg/kg/day), which is above approved doses.
Price Impact
More from CPRX